Annexon (ANNX) Competitors $2.40 -0.11 (-4.20%) As of 12:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANNX vs. ELVN, GPCR, CDTX, ARDX, PRAX, PROK, COLL, AKBA, AMPH, and RCUSShould you be buying Annexon stock or one of its competitors? The main competitors of Annexon include Enliven Therapeutics (ELVN), Structure Therapeutics (GPCR), Cidara Therapeutics (CDTX), Ardelyx (ARDX), Praxis Precision Medicines (PRAX), ProKidney (PROK), Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Amphastar Pharmaceuticals (AMPH), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. Annexon vs. Its Competitors Enliven Therapeutics Structure Therapeutics Cidara Therapeutics Ardelyx Praxis Precision Medicines ProKidney Collegium Pharmaceutical Akebia Therapeutics Amphastar Pharmaceuticals Arcus Biosciences Annexon (NASDAQ:ANNX) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends. Is ANNX or ELVN more profitable? Enliven Therapeutics' return on equity of -31.84% beat Annexon's return on equity.Company Net Margins Return on Equity Return on Assets AnnexonN/A -54.45% -46.56% Enliven Therapeutics N/A -31.84%-30.09% Do insiders and institutionals believe in ANNX or ELVN? 95.1% of Enliven Therapeutics shares are held by institutional investors. 12.7% of Annexon shares are held by insiders. Comparatively, 25.9% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger valuation and earnings, ANNX or ELVN? Enliven Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnexonN/AN/A-$138.20M-$1.18-2.03Enliven TherapeuticsN/AN/A-$89.02M-$1.92-11.46 Which has more risk and volatility, ANNX or ELVN? Annexon has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Does the media refer more to ANNX or ELVN? In the previous week, Enliven Therapeutics had 4 more articles in the media than Annexon. MarketBeat recorded 11 mentions for Enliven Therapeutics and 7 mentions for Annexon. Annexon's average media sentiment score of 0.58 beat Enliven Therapeutics' score of 0.57 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ANNX or ELVN? Annexon presently has a consensus target price of $12.50, suggesting a potential upside of 421.92%. Enliven Therapeutics has a consensus target price of $41.20, suggesting a potential upside of 87.23%. Given Annexon's higher probable upside, equities research analysts clearly believe Annexon is more favorable than Enliven Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annexon 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryEnliven Therapeutics beats Annexon on 7 of the 12 factors compared between the two stocks. Get Annexon News Delivered to You Automatically Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANNX vs. The Competition Export to ExcelMetricAnnexonMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$261.66M$2.92B$5.56B$9.26BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-2.0220.2728.5819.56Price / SalesN/A298.79434.47183.65Price / CashN/A43.1536.0257.93Price / Book0.877.668.165.58Net Income-$138.20M-$55.11M$3.24B$257.82M7 Day Performance-13.54%0.03%-0.64%-0.39%1 Month Performance-1.84%7.47%4.93%7.80%1 Year Performance-61.25%-3.28%26.04%12.95% Annexon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANNXAnnexon2.5041 of 5 stars$2.40-4.2%$12.50+421.9%-59.5%$261.66MN/A-2.0260Positive NewsELVNEnliven Therapeutics2.7935 of 5 stars$23.00+2.4%$41.20+79.1%-13.7%$1.13BN/A-11.9850GPCRStructure Therapeutics2.8996 of 5 stars$19.57+2.9%$76.17+289.2%-56.8%$1.12BN/A-22.49136Positive NewsCDTXCidara Therapeutics4.175 of 5 stars$55.32+9.5%$57.29+3.6%+311.9%$1.12B$1.27M-1.8890High Trading VolumeARDXArdelyx4.0638 of 5 stars$4.61+2.7%$10.89+136.2%-24.4%$1.10B$333.61M-20.9590Analyst RevisionPRAXPraxis Precision Medicines2.2462 of 5 stars$53.60+6.1%$94.11+75.6%+1.8%$1.09B$8.55M-5.00110News CoverageAnalyst RevisionPROKProKidney3.5244 of 5 stars$3.69-18.7%$5.67+53.6%+41.0%$1.08B$306K-6.153Trending NewsAnalyst ForecastHigh Trading VolumeCOLLCollegium Pharmaceutical4.2854 of 5 stars$32.83+1.0%$43.75+33.3%+0.7%$1.05B$631.45M26.91210Buyback AnnouncementAKBAAkebia Therapeutics3.6534 of 5 stars$3.97+1.0%$6.75+70.0%+196.2%$1.04B$160.18M-18.90430AMPHAmphastar Pharmaceuticals4.292 of 5 stars$21.95+1.3%$32.33+47.3%-45.4%$1.03B$731.97M7.952,028RCUSArcus Biosciences2.3057 of 5 stars$9.66+3.5%$21.29+120.5%-41.5%$1.02B$258M-2.30500 Related Companies and Tools Related Companies ELVN Competitors GPCR Competitors CDTX Competitors ARDX Competitors PRAX Competitors PROK Competitors COLL Competitors AKBA Competitors AMPH Competitors RCUS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANNX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annexon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANNX Stock Alerts